Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Making Pharmacovigilance a Company-Wide Responsibility

Posted on June 20th, 2016 by



The scope of pharmacovigilance has expanded. Regulatory agencies have placed new demands on how pharmaceutical companies are expected to ensure the safety of their products and manage benefit–risk. Continue reading “Making Pharmacovigilance a Company-Wide Responsibility” »

A Holistic Cure for the Pharmaceutical Industry’s Ailments

Posted on June 17th, 2016 by

Pharma R&D


Since the turn of the century, the pharmaceutical industry has seen dramatic changes, including dwindling drug pipelines, looming patent expirations and rising costs. Continue reading “A Holistic Cure for the Pharmaceutical Industry’s Ailments” »

Reducing the Risk of Late-Stage Failure with In Silico Modeling

Posted on June 15th, 2016 by

Pharma R&D


In silico modeling is arguably one of the hottest trends in life sciences R&D today. We know that bringing drug discovery to the desktop impacts cost. Continue reading “Reducing the Risk of Late-Stage Failure with In Silico Modeling” »

PV Poll: Using Text Mining in Literature Surveillance

Posted on June 14th, 2016 by



We have spoken to several pharmacovigilance teams that are looking into using text mining tools as part of their literature monitoring process.   Continue reading “PV Poll: Using Text Mining in Literature Surveillance” »

Biotech by the Bay

Posted on June 13th, 2016 by

Pharma R&D


The Bay Area was a hotbed of biotech conversation and activity this past week, as the BIO International Convention hit San Francisco from June 6-9. The convention is self-dubbed as “The Global Event for Biotechnology,” and that is not hyperbole. Continue reading “Biotech by the Bay” »

Sources of Innovation for Drugs of the Future

Posted on June 6th, 2016 by

Pharma R&D


Innovative drug targets are necessary if precision medicine is to become the norm. Collaboration will be the enabler in developing novel drug therapies: Continue reading “Sources of Innovation for Drugs of the Future” »

  1. 1
  2. …
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47
  8. …
  9. 57

About this Blog


The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.